Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era

Urology

Volumn 45, Issue 5, 1995, Pages 729-744

  McCormack, Robert T ^a,b,c   Wang, T J ^a,b,c   Rittenhouse, Harry G ^a,b,c   Wolfert, Robert L ^a,b,c   Finlay, Judith A ^a,b,c   Lilja, Hans ^a,b,c   Okoloff, Roger L ^a,b,c   Oesterling, Joseph E ^a,b,c  

^a Hybritech Incorporated   (United States)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; KALLIKREIN; PROSTATE SPECIFIC ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN DETECTION; ANTIGEN RECOGNITION; HUMAN; MULTIGENE FAMILY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN DETERMINATION; PROTEIN FAMILY; REVIEW;

AMINO ACID SEQUENCE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN; KALLIKREINS; MALE; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TERMINOLOGY; TUMOR MARKERS, BIOLOGICAL;

EID: 0028863610     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80076-4     Document Type: Review

References (131)

1. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination, and prostate specific antigen
2. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
3. Screening for prostatic carcinoma with prostate specific antigen
4. Serum prostate specific antigen as pr-screening test for prostate cancer
5. Comparison of digital rectal examination and serum prostate specific antigen (PSA) in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men
6. A complex between prostatespecific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer
7. 1-antichymotrypsin as an indicator of prostate cancer
8. Prostate-specific antigen in screening of prostate cancer
9. Prostate-specific antigen: biochemistry, analytical methods, and clinical application
10. Prostate-specific antigen: enzyme activity and reactions with extracellular protease inhibitors
11. Isolation of nine human plasma proteinase inhibitors by sequential affinity chromatography
12. Structure, function, and regulation of the enzyme activity of prostate-specific antigen
13. PSA leads the way for detecting and following prostate cancer
14. Definition of the ideal tumor marker.
15. Trends in immunoassays of prostatespecific antigen: serum complexes and ultrasensitivity
16. Prostate-specific antigen and human glandular kallikrein: two kallikreins of the human prostate
17. Characterization of the gene for prostatespecific antigen, a human glandular kallikrein
18. Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats
19. A common nomenclature for members of the tissue (glandular) kallikrein gene families. Recent progress on kinins
20. The molecular biology of the kallikrein-kinin system: III. The human kallikrein gene family and kallikrein substrate
21. The human kallikrein gene family: a diversity of expression and function
22. Characterization of the human kallikrein locus
23. Purification and characterization of human salivary-gland prokallikrein from recombinant baculovirusinfected insect cells
24. Nucleotide sequence of cloned cDNA for human pancreatic kallikrein
25. Expression of human salivary-gland kallikrein in insect cells by a baculovirus vector. Recent progress on kinins
26. Primary structure of a human glandular kallikrein gene
27. Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5′ promoter region of the gene
28. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein
29. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen
30. Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate
31. Overexpression of a human prostate-specific glandular kallikrein, hK2 in E. coli and generation of antibodies
32. Purification of human prostate-specific antigen
33. Prostate-specific antigen
34. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay
35. False positive prostate specific antigen values in the sera of women with renal cell carcinoma
36. Re False positive prostate specific antigen values in the sera of women with renal cell carcinoma
37. Some physico-chemical characteristics of “γ-seminoprotein,” an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII. Nippon Hoigaku Zasshi
38. Isolation and characterization of two specific antigens of human seminal plasma
39. Isolation and characterization of a semen-specific protein from human seminal plasma: a potential new marker for semen identification
40. Prostate antigen: a new potential marker for prostatic cancer
41. A prostate antigen in sera of prostatic cancer patients
42. Isolation, characterization and amino-acid sequence of gamma-seminoprotein, a glycoprotein from human seminal plasma
43. Human prostate-specific antigen: structural and functional similarity with serine proteases
44. Molecular cloning of human prostate specific antigen cDNA
45. Immunoassay analytical recovery of prostatespecific antigen purified from seminal fluid
46. Physicochemical characterization of prostate antigen purified from human prostate gland and seminal plasma
47. Prostatespecific antigen, p30, γ-seminoprotein, and E1
48. Immunoelectron microscopic localization of prostatic-specific antigen in human prostate by the protein a-gold complex
49. Immunoreactive prostatic specific antigen in male periurethral glands
50. Prostate antigen: a marker for human prostate epithelial cells
51. In situ hybridization of prostate-specific antigen mRNA in human prostate
52. Urinary prostate specific antigen levels after radical prostatectomy
53. An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands
54. Excretion of three major prostatic secretory proteins in the urine of normal men and patients with benign prostatic hypertrophy or prostate cancer
55. Urinary prostate specific antigen levels: role in monitoring the response of prostate cancer to therapy
56. Production of prostate specific antigen by breast tumors
57. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age
58. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium
59. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays
60. Reverse transcription polymerase chain reaction (RT-PCR) detects metastatic prostate cancer cells in lymph nodes, blood and potentially in bone marrow using PSA-mRNA as template
61. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay
62. Prostatespecific antigen and prostatitis 1. Effect of prostatitis on serum PSA in the human and non-human primate
63. Characterization of rhesus monkey prostate specific antigen cDNA
64. Speciesand organ-specificity of secretory proteins derived from human prostate and seminal vesicles
65. New concepts in studying the control of normal and cancer growth of prostate
66. Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard.
67. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein
68. Pitfalls in the differentiation of N-glycosylation variants of prostate-specific antigen using concanavalin-A
69. Occurrence of the Y determinant on the N-glycosidic carbohydrate units of human γ-seminoprotein
70. Role of proteolytic enzymes in biological regulation
71. The versatility of proteolytic enzymes
72. Molecular biology of tissue kallikrein
73. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors
74. Seminal plasma protein p30: simplified purification and evidence for identity with prostate specific antigen
75. A quantitative ELISA for the measurement of complexes of prostate-specific antigen with protein C inhibitor when using a purified standard.
76. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen
77. Molecular cloning of epididymal and seminal vesicular transcripts encoding a semenogelin-related protein
78. Seminal vesicle-secreted proteins and their reactions during gelation and liquification of human semen
79. Prostate-specific antigen (PSA) is an insulin-like growth-factor binding protein-3 protease found in seminal plasma
80. Prostate specific antigen releases a kinin-like substance that stimulates smooth muscle contraction
81. Protein C. Inhibitor in human body fluids, seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system
82. The biology and biochemistry of antichymotrypsin and its potential role as a therapeutic agent
83. The glandular kallikrein family of enzymes: tissue specific-expression and hormonal regulation
84. 2macroglobulin structure and function
85. 2-macroglobulin
86. α-Macroglobulins: structure, shape, and mechanism of proteinase complex formation
87. 1antichymotrypsin
88. 1-antichymotrypsin
89. Prostate-specific antigenic domain of human prostate specific antigen identified with monoclonal antibodies
90. Characterization and measurement of prostate-specific antigen using monoclonal antibodies
91. Clinical evaluation of a new prostate-specific antigen sandwich ELISA which employs four monoclonal antibodies directed at different epitopes of prostate-specific antigen
92. ® of free and total forms of prostate specific antigen for differentiation of patients with benign prostatic hyperplasia and prostate cancer
93. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays
94. 1-antichymotrypsin
95. Serum prostate specific antigen complexed to alpha 1antichymotrypsin as an indicator of prostate cancer
96. 1-antichymotrypsin in blood
97. Prognostic implications of disappearance rate of biologic markers following radical prostatectomy
98. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy
99. 1-proteinase inhibitor, antithrombin II and heparin cofactor II
100. Human plasma proteinase inhibitors
101. The disappearance of enzyme-inhibitor complexes from the circulation of man
102. Effect of prostate specific antigen forms on PSA quantitation
103. Issues on standardization of immunoassays for prostate-specific antigen: a review
104. Standardization of immunoassays for prostate-specific antigen—a problem of prostate-specific antigen complexation or a problem of assay design?
105. Comparability of the Tandem-R and IMx assays for the measurement of serum prostate-specific antigen
106. Standardization of immunoassays for prostate-specific antigen: a different view based on experimental observations
107. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
108. Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study
109. Sustained, substantially increased concentration of prostatespecific antigen in the absence of prostatic malignant disease: an unusual clinical scenario
110. The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer
111. Prostate specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer
112. Clinical use of prostate specific antigen in patients with prostate cancer
113. Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen
114. The value of serum prostate specific antigen determinations before and after radical prostatectomy
115. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia
116. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organconfined prostate cancer
117. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer
118. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen
119. PSA density (PSAD): role in patient evaluation and management
120. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
121. Longitudinal changes in serum PSA (PSA velocity) in a community-based cohort of men
122. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges
123. Derivation of normal prostate specific antigen (PSA) level by age
124. Report on the 1993 Prostate Cancer Awareness Week
125. Relationship between prostate specific antigen, prostate volume and age in the benign prostate
126. Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma
127. 1-antichymotrypsin by PSA-containing cells of human prostate epithelium
128. 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia
129. Free, complexed and total serum PSA: establishment of age-specific reference ranges using newly developed immunofluorometric assays (IFMA)
130. Improved separation between normals, benign prostatic hyperplasia (BPH), and carcinoma of the prostate (CAP) by measuring free (F), complexed (C) and total concentrations (T) of prostate specific antigen